- Organon is a global healthcare company focused on women's health and general medicines, with reported revenues of $6.2 billion in 2025, reflecting a 3% decline from the previous year.
- In April 2026, Sun Pharmaceutical Industries announced a binding offer of $12 billion to acquire Organon, marking a significant potential shift in the company's ownership and strategic direction.
- Organon maintains partnerships in the healthcare sector, particularly focusing on women's health products, although specific key customers were not detailed in the recent reports.
- Ideal buyers for Organon are healthcare providers and organizations focused on women's health solutions, as the company aims to address gaps in treatment and improve patient outcomes in this area.
The workforce is organized across 17 departments, with Operations being the largest at 190 employees, followed closely by Information Technology with 161 staff members. The Executive department comprises 135 individuals, indicating a strong leadership presence. Other notable departments include Health Services and Sales, with headcounts of 129 and 128, respectively. This distribution reflects a balanced functional mix, supporting both operational efficiency and strategic initiatives.
The company operates in 175 locations, with a significant concentration in New Jersey. West Orange, NJ, leads with 114 employees, followed by Kenilworth, NJ, at 50 and Whitehouse Station, NJ, with 29. The presence of 1,449 employees in the 'Other' category suggests a widespread geographic distribution, indicating a robust remote or distributed workforce model. This distribution helps the company leverage regional talent while maintaining operational effectiveness.
